Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection
Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial
1 other identifier
interventional
300
1 country
1
Brief Summary
The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable covid19
Started Apr 2020
Shorter than P25 for not_applicable covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2020
CompletedFirst Submitted
Initial submission to the registry
November 6, 2020
CompletedFirst Posted
Study publicly available on registry
November 10, 2020
CompletedNovember 10, 2020
November 1, 2020
4 months
November 6, 2020
November 7, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
time to fever control
time to complete resolution of fever
15 days
Secondary Outcomes (1)
PCR conversion
15 days
Study Arms (3)
clarithromycin
EXPERIMENTALclarithromycin group
Azithromycin
ACTIVE COMPARATORazithromycin group
control
PLACEBO COMPARATORcontrol group
Interventions
Eligibility Criteria
You may qualify if:
- COVID-19 cases
- Oxygen saturation \> 93%
- Age \>18 years
You may not qualify if:
- Patients \<18 years,
- patients with Oxygen saturation \< 93%, patients with
- Diabetes mellitus or
- heart failure,
- patients on chemotherapy or immunosuppressive therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
south-Vally University faculty of medicine
Qina, Qena Governorate, 868532, Egypt
Related Publications (1)
Rashad A, Nafady A, Hassan MH, Mansour H, Taya U, Bazeed SES, Aref ZF, Sayed MAA, Nafady-Hego H, Abdelmaksoud AA. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. Sci Rep. 2021 Aug 11;11(1):16361. doi: 10.1038/s41598-021-95900-z.
PMID: 34381155DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alaa Rashad, MD
associate professor
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- double-blinded
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor of chest diseases
Study Record Dates
First Submitted
November 6, 2020
First Posted
November 10, 2020
Study Start
April 1, 2020
Primary Completion
July 30, 2020
Study Completion
July 30, 2020
Last Updated
November 10, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share